• 2915 Citations
1990 …2021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

The primary focus of the Kiser research group is developing and translating new drug delivery technologies for the prevention and treatment of HIV infection. We are particularly interested in new antiviral agents and drug delivery systems to intercept sexually transmitted viruses at the point of interaction with the genital mucosa and the first target cells infected in the mucosa. Our methods include synthetic polymer chemistry, pharmaceutical chemistry, modeling drug transport, and using these results in drug delivery system design and prototyping. We perform preclinical toxicity efficacy evaluations in cell, tissue, and animal models; conduct antiviral assays and drug transport assays; and produce devices using a variety of pharmaceutical manufacturing technologies. Our projects range from new materials discovery that could lead to next generation mucosally active antiviral agents and mucosal vaccines, to the development of new assays to evaluate HIV prevention technologies, to sustained delivery system projects for antiviral, anti-infectives and contraceptive agents. The lab is funded by the NIH (NIAD), the Bill and Melinda Gates Foundation and USAID.

Education/Academic qualification

Mechanical Engineering and Materials Science, PhD, Duke University

… → 1999

MS, University of Wisconsin-Milwaukee

… → 1989

Chemistry and Philosophy, BS, University of Wisconsin-Madison

Fingerprint Dive into the research topics where Patrick Kiser is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


  • Research Output

  • 2 Scopus citations

    Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women

    Thurman, A. R., Schwartz, J. L., Brache, V., Clark, M. R., McCormick, T., Chandra, N., Marzinke, M. A., Stanczyk, F. Z., Dezzutti, C. S., Hillier, S. L., Herold, B. C., Fichorova, R., Asin, S. N., Rollenhagen, C., Weiner, D., Kiser, P. & Doncel, G. F., Jun 2018, In : PloS one. 13, 6, e0199778.

    Research output: Contribution to journalArticle

  • 14 Scopus citations

    A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates

    Su, J. T., Teller, R. S., Srinivasan, P., Zhang, J., Martin, A., Sung, S., Smith, J. M. & Kiser, P. F., Oct 1 2017, In : Pharmaceutical Research. 34, 10, p. 2163-2171 9 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Long-term direct visualization of passively transferred fluorophore-conjugated antibodies

    Schneider, J. R., Carias, A. M., Bastian, A. R., Cianci, G. C., Kiser, P. F., Veazey, R. S. & Hope, T. J., Nov 2017, In : Journal of Immunological Methods. 450, p. 66-72 7 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations

    Preferences for Long-Acting Pre-exposure Prophylaxis (PrEP), Daily Oral PrEP, or Condoms for HIV Prevention Among U.S. Men Who Have Sex with Men

    Greene, G. J., Swann, G., Fought, A. J., Carballo-Diéguez, A., Hope, T. J., Kiser, P. F., Mustanski, B. & D’Aquila, R. T., May 1 2017, In : AIDS and behavior. 21, 5, p. 1336-1349 14 p.

    Research output: Contribution to journalArticle

  • 40 Scopus citations